Lixisenatide 10micrograms/0.2ml solution for injection 3ml pre-filled disposable devices

The activation of the GLP-1 receptor by lixisenatide results in the activation of adenylyl cyclase.[A19193] This increases the concentration of cyclic adenosine monophosphate in the cell leading to the activation of protein kinase A (PKA) as well as Epac1 and Epac2. PKA, Epac1, and Epac2 are involved the in release of Ca2+ from the endoplasmic reticulum which is known as the "amplification" pathway which increases insulin release when the triggering pathway is activated. By activating this amplification pathway lixisenatide increases glucose stimulated insulin secretion.